Company performance
Add to research
Current Price
as of Jul 11, 2025$21.40
P/E Ratio
12.01
Market Cap
$13.27B
Description
Add to research
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Metrics
Add to research
Overview
- HQCopenhagen, CD
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerGMAB
- Price$21.4-2.10%
Trading Information
- Market cap$13.27B
- Float100.00%
- Average Daily Volume (1m)1,642,370
- Average Daily Volume (3m)1,423,309
- EPS$1.78
Company
- Revenue$3.23B
- Rev growth (1yr)18.64%
- Net income$195.13M
- Gross margin94.13%
- EBITDA margin28.53%
- EBITDA$204.14M
- EV$9.44B
- EV/Revenue2.92
- P/E12.01
- P/S4.23
- P/B2.57
- Debt/Equity2.70
Documents
Add to research